Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Selexis
Plan-les-Ouates/Geneva, Geneva, Switzerland
- Ownership
- Private
- Employees
- ~53
- Development stage
- Commercial
01
Overview
Selexis pioneered mammalian cell line generation with its SUREtechnology Platform™, enabling rapid and stable production of recombinant proteins. Its technologies are used by global biopharmaceutical partners to accelerate the discovery, development, and commercialization of biologics and vaccines. Over ten commercial products use Selexis-derived cell lines; more than one hundred sixty drug candidates developed using their platforms are at various stages from preclinical to clinical trials. The company was acquired by JSR Life Sciences in 2017 and integrated into KBI Biopharma operations in 2023 to provide end-to-end CDMO services.
- Therapeutic areas
- Metabolic DisordersImmunologyDermatologyHematologyOncology
- Modalities
- Recombinant proteinMonoclonal antibodyBiologicVaccine
- Industry
- Contract Manufacturing Organization
02
Partnerships
Over one hundred global biopharmaceutical partners utilizing the SUREtechnology Platform™ for drug development; specific names not disclosed publicly.
Beyond the preview
Go deeper on Selexis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Selexis.